Understanding Tysabri and PML Risk: What Patients and Clinicians Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Occupational Exposure: The Legacy Context

If you or someone you know is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical for informed decision-making. The medical community has long emphasized the importance of balancing therapeutic benefits with potential adverse effects, a principle that guides this discussion. This page provides an overview of PML monitoring strategies and clinical considerations relevant to New Jersey patients.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The label emphasizes that these factors 'should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents lymphocyte migration across the blood-brain barrier, reducing immune surveillance in the central nervous system. This immunosuppressive effect in the brain allows latent JC virus to reactivate and cause PML. The clinical presentation of PML includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and ataxia. Diagnosis is typically confirmed by MRI findings and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction.

Legal Implications: Statute of Limitations for Tysabri Claims in New Jersey

The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The FDA-approved label includes a boxed warning and requires enrollment in the TOUCH Prescribing Program, a restricted distribution program designed to ensure that patients are informed of the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must read the Medication Guide, understand the risks, and sign a Patient Enrollment Form. Pharmacies and infusion centers must be certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients have developed PML and subsequently pursued legal claims, alleging that the warnings were insufficient or that the risks were not adequately communicated. For affected patients in New Jersey, settlement-related considerations involve the statute of limitations for product liability claims. In New Jersey, the statute of limitations for personal injury actions, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical for patients who developed PML after Tysabri exposure. The date of discovery may be when the patient first experienced symptoms consistent with PML, or when a diagnosis was confirmed. Given that PML can progress rapidly, early recognition is essential. The timeline between Tysabri exposure and documented harm varies; PML has been reported after a few months to several years of treatment, with longer duration increasing risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Settlements in Tysabri-related PML cases often consider the severity of disability, medical expenses, lost income, and pain and suffering. The boxed warning explicitly states that PML 'usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who survive may require long-term care. Legal claims may also involve allegations of failure to warn, design defect, or negligence. The TOUCH program's role in risk mitigation is a factor in evaluating whether the manufacturer fulfilled its duty to warn. In summary, Tysabri carries a known risk of PML, with identifiable risk factors including anti-JCV antibodies, treatment duration, and prior immunosuppressant use. The FDA label provides clear warnings, but patients who develop PML may have legal recourse. In New Jersey, the statute of limitations for such claims is two years from discovery of the injury. Patients and their families should seek legal advice promptly to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in New Jersey?

In New Jersey, the statute of limitations for personal injury actions, including those related to pharmaceutical products like Tysabri, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this is typically when symptoms first appear or when a diagnosis is confirmed.

What are the primary risk factors for developing PML while on Tysabri?

The three primary risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.